Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)

Summary

The objective is to show superior efficacy of PTH (1-84) over risedronate in treating osteoporotic women for 12 months after having previously been treated with PTH (1-84) for 12 months followed by 12 months treatment with risedronate.

Timeline

Start

2006-07

Primary completion

2011-01

Completion

2011-08

Outcome

Met primary endpoint

registry analysis (superiority or other test); PTH (1-84) vs Risedronate; p = 0.010; Mean Difference (Final Values) 1.012 (95% CI 1.003 to 1.021); ANCOVA NCT00365456 ↗

Drugs

Indications